Statera Biopharma (STAB) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 11, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'CLEVELAND BIOLABS INC	'
Entity Central Index Key	'0001318641	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	57,110,198

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$11,103,596	$10,048,466
Short-term investments	'	305,538
Accounts receivable	392,696	458,391
Other current assets	477,339	344,386
Total current assets	11,973,631	11,156,781
Equipment, net	335,230	457,912
Restricted cash	2,843,413	2,921,724
Other long-term assets	74,663	159,224
Total assets	15,226,937	14,695,641
Current liabilities:	'	'
Accounts payable	719,637	794,397
Accrued expenses	2,122,690	2,445,446
Deferred revenue	744,500	1,069,438
Accrued warrant liability	1,024,720	1,241,311
Current portion of notes payable	481,903	351,527
Current portion of capital lease obligation	50,827	83,634
Total current liabilities	5,144,277	5,985,753
Noncurrent portion of capital lease obligation	'	7,522
Long-term debt	3,634,034	7,121,388
Commitments and contingencies	'	'
Total liabilities	8,778,311	13,114,663
Stockholders' equity:	'	'
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	'	'
Common stock, $.005 par value; 160,000,000 shares authorized, 57,110,198 and 45,182,114 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	285,551	225,911
Additional paid-in capital	134,201,257	125,508,471
Accumulated other comprehensive income	236,497	307,339
Accumulated deficit	-141,111,199	-135,564,666
Total Cleveland BioLabs, Inc. stockholders' deficit	-6,387,894	-9,522,945
Noncontrolling interest in stockholders' equity	12,836,520	11,103,923
Total stockholders' equity	6,448,626	1,580,978
Total liabilities and stockholders' equity	$15,226,937	$14,695,641

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	57,110,198	45,182,114
Common stock, shares outstanding	57,110,198	45,182,114

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Grants and contracts	$562,087	$1,613,262	$1,896,341	$2,980,734
Operating expenses:	'	'	'	'
Research and development	2,324,223	5,373,029	4,763,996	10,704,644
General and administrative	2,250,368	3,016,851	4,663,911	6,500,223
Total operating expenses	4,574,591	8,389,880	9,427,907	17,204,867
Loss from operations	-4,012,504	-6,776,618	-7,531,566	-14,224,133
Other income (expense):	'	'	'	'
Interest and other income (expense)	-623,786	47,809	-941,708	127,765
Foreign exchange gain (loss)	92,594	46,776	-59,177	74,910
Change in value of warrant liability	412,125	2,795,612	2,499,683	-652,111
Total other income (expense)	-119,067	2,890,197	1,498,798	-449,436
Net loss	-4,131,571	-3,886,421	-6,032,768	-14,673,569
Net loss attributable to noncontrolling interests	170,410	844,310	486,235	1,867,135
Net loss attributable to Cleveland BioLabs, Inc.	($3,961,161)	($3,042,111)	($5,546,533)	($12,806,434)
Net loss available to common stockholders per share of common stock, basic and diluted	($0.08)	($0.07)	($0.11)	($0.29)
Weighted average number of shares used in calculating net loss per share, basic and diluted	51,891,629	44,948,591	50,935,194	44,887,920

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Net loss including noncontrolling interests	($4,131,571)	($3,886,421)	($6,032,768)	($14,673,569)
Other comprehensive loss	'	'	'	'
Foreign currency translation adjustment	199,052	-282,622	-92,414	-440,069
Comprehensive loss including noncontrolling interests	-3,932,519	-4,169,043	-6,125,182	-15,113,638
Comprehensive loss attributable to noncontrolling interests	90,531	961,118	507,807	2,049,198
Comprehensive loss attributable to Cleveland BioLabs, Inc.	($3,841,988)	($3,207,925)	($5,617,375)	($13,064,440)

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interests [Member]
Beginning balance at Dec. 31, 2013	$1,580,978	$225,911	$125,508,471	$307,339	($135,564,666)	$11,103,923
Beginning balance, Shares at Dec. 31, 2013	'	45,182,114	'	'	'	'
Stock based compensation	476,441	'	476,441	'	'	'
Stock based compensation, Shares	'	'	'	'	'	'
Issuance of shares for compensation	15,625	115	15,510	'	'	'
Issuance of shares for compensation, Shares	'	22,978	'	'	'	'
Issuance of common stock, net of offering costs	9,802,118	59,525	9,742,593	'	'	'
Issuance of common stock, net of offering costs, shares	'	11,905,106	'	'	'	'
Allocation of equity proceeds to fair value of warrants	-2,216,593	'	-2,216,593	'	'	'
Noncontrolling interest capital contribution	2,915,239	'	674,835	'	'	2,240,404
Net loss	-6,032,768	'	'	'	-5,546,533	-486,235
Foreign currency translation	-92,414	'	'	-70,842	'	-21,572
Ending balance at Jun. 30, 2014	$6,448,626	$285,551	$134,201,257	$236,497	($141,111,199)	$12,836,520
Ending balance, Shares at Jun. 30, 2014	'	57,110,198	'	'	'	'

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (Common Stock [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Common Stock [Member]	'
Offering costs	$697,882

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($6,032,768)	($14,673,569)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	107,958	189,840
Amortization	578,513	'
Loss on equipment disposal	24,685	'
Noncash compensation	182,617	1,122,857
Warrant issuance costs	171,116	'
Change in value of warrant liability	-2,499,683	652,111
Changes in operating assets and liabilities:	'	'
Accounts receivable	76,532	-1,155,910
Other current assets	-132,834	303,845
Other long-term assets	15,879	-16,801
Accounts payable	-47,251	-322,004
Deferred revenue	-284,847	-661,811
Accrued expenses	114,081	437,647
Net cash used in operating activities	-7,726,002	-14,123,795
Cash flows from investing activities:	'	'
Sale of short-term investments	285,881	2,256,834
Purchase of equipment	-10,803	-85,800
Net cash provided by investing activities	275,078	2,171,034
Cash flows from financing activities:	'	'
Issuance of common stock, net of offering costs	9,697,501	'
Repayment of long-term debt	-4,000,000	'
Noncontrolling interest capital contribution to Incuron, LLC	2,915,239	'
Exercise of options	'	12,392
Repayment of capital lease obligation	-40,329	-40,568
Net cash provided by (used in) financing activities	8,572,411	-28,176
Effect of exchange rate change on cash and equivalents	-66,357	-425,749
Increase (decrease) in cash and cash equivalents	1,055,130	-12,406,686
Cash and cash equivalents at beginning of period	10,048,466	25,652,083
Cash and cash equivalents at end of period	11,103,596	13,245,397
Supplemental disclosure of cash flow information:	'	'
Cash paid during the period for interest	360,642	12,714
Supplemental schedule of noncash financing activities:	'	'
Noncash financing costs on common stock offering	50,505	'
Noncash warrant issuance costs	$15,993	'

Description_of_Business

Description of Business	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Description of Business	'
	1.  Description of Business
	Cleveland BioLabs, Inc., or CBLI, or the Company, is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. Our lead product candidates are entolimod, which we are developing for a biodefense indication and as an oncology drug, and Curaxin CBL0137, our lead oncology product candidate. We conduct business in the United States and in the Russian Federation through several legal entities, some of which are majority-owned in collaboration with financial partners.
	CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. As of June 30, 2014, CBLI had one wholly-owned operating subsidiary, BioLab 612, LLC, or BioLab 612, which began operations in 2012 and two majority-owned operating subsidiaries, Incuron, LLC, or Incuron, and Panacela Labs, Inc., or Panacela, which were formed in 2010 and 2011, respectively. Additionally, Panacela had a wholly-owned operating subsidiary, Panacela Labs, LLC.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2.  Summary of Significant Accounting Policies
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of CBLI and its subsidiaries, BioLab 612, Incuron and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
	In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2014, along with its results of operations for the three and six month periods ended June 30, 2014 and 2013 and cash flows for the six month periods ended June 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Of the $11.1 million and $10.0 million of cash and cash equivalents at June 30, 2014 and December 31, 2013, respectively, $0.0 million and $3.5 million, respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of June 30, 2014, $3.4 million of the Company’s cash and cash equivalents was restricted to the use of its majority-owned subsidiaries, leaving $7.7 million available for general use.
	Significant Customers and Accounts Receivable
	Grant and contract revenue from the U.S. government accounted for 0% and 1.2% of total revenue for the three and six months ended June 30, 2014, respectively, and 37.7% and 34.8% of total revenue for the three and six months ended June 30, 2013, respectively. Grant and contract revenue received by the Company’s subsidiaries from Russian government agencies accounted for 100% and 98.8% of total revenues for the three and six months ended June 30, 2014, respectively, and 62.3% and 65.2% of total revenues for the three and six months ended June 30, 2013, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future.
	Accounts receivable consist of amounts due under reimbursement contracts with certain government and foreign entities. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 days.
	Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were no allowances for doubtful accounts as of June 30, 2014 and December 31, 2013, as the collection history from the Company’s customers indicated that collection was probable.
	Intellectual Property
	Costs related to filing and pursuing patent applications are recognized as general and administrative expenses, or G&A expenses, as incurred, since the recoverability of such expenditures is uncertain. Upon marketing approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
	Accounting for Stock-Based Compensation
	The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of June 30, 2014, an aggregate of 10.0 million shares of common stock were authorized for issuance under the Plan, of which a total of approximately 1.5 million shares of common stock remained available for future awards. A single participant cannot be awarded more than 400,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s compensation committee.
	In June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of Common Stock. As of June 30, 2014, there are 2.3 million shares of Common Stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i) 10% of the total number of shares of Common Stock outstanding on December 31st of the preceding year, or (ii) 200,000 shares of Common Stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of Common Stock at an amount equal to 85% of the fair market value of the Company’s Common Stock on the offering date or the purchase date, whichever is less.
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the six months ended June 30,
		2014		2013
	Risk-free interest rate	1.59 - 1.98%		0.02 - 1.92%
	Expected dividend yield	0%		0%
	Expected life	5 - 6 Years		5 - 7.3 Years
	Expected volatility	71.24 - 77.99%		80.71 - 89.66%
	“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
	“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
	“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
	“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
	Income Taxes
	No income tax expense was recorded for the three and six months ended June 30, 2014 and 2013, as the Company does not expect to have taxable income for 2014 and did not have taxable income in 2013. A full valuation allowance has been recorded against the Company’s deferred tax asset.
	Earnings (Loss) per Share
	Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of June 30,
	Common Equivalent Securities	2014			2013
	Warrants		20,614,204			10,377,995
	Options		6,224,107			5,683,944
	Total		26,838,311			16,061,939
	Contingencies
	From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company is not a party to any pending material litigation that is estimable and probable of loss.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	3.  Fair Value of Financial Instruments
	The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes:
	Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets;
	Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
	Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.
	The following tables represent the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013:
			As of June 30, 2014
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,024,720		$	1,024,720
	Total liabilities		$	—		$	—		$	1,024,720		$	1,024,720
			As of December 31, 2013
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311		$	1,241,311
	Compensatory stock options not yet issued			—			—			309,450			309,450
	Total liabilities		$	—		$	—		$	1,550,761		$	1,550,761
	The Company uses the Black-Scholes model to measure the accrued warrant liability and its accrual for compensatory stock options not yet issued. The following are the assumptions used to measure the accrued warrant liability at June 30, 2014 and December 31, 2013, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2:
			June 30, 2014		December 31, 2013
	Stock Price		$0.48		$1.17
	Exercise Price		$0.505 - 5.00		$1.60 - 5.00
	Term in years		0.34 - 4.54		0.59 - 1.91
	Volatility		61.15 - 82.14%		42.52 - 76.03%
	Annual rate of quarterly dividends		0%		0%
	Discount rate- bond equivalent yield		.04 - 1.45%		.08 -  .36%
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the six months ended June 30, 2014 and 2013:
			Three months ended June 30, 2014						Six months ended June 30, 2014
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	1,436,845		$	—		$	1,241,311		$	309,450
	Issuances			—			—			2,283,092			—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(412,125	)		—			(2,499,683	)		(21,055	)
	Settlements			—			—			—			(288,395	)
	Balance, June 30, 2014		$	1,024,720		$	—		$	1,024,720		$	—
			Three months ended June 30, 2013						Six months ended June 30, 2013
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	7,553,382		$	63,641		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)			(2,795,612	)		—			652,111			—
	Estimates and other changes in fair value (2)			—			197			—			63,838
	Balance, June 30, 2013		$	4,757,770		$	63,838		$	4,757,770		$	63,838
	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the three months ended June 30, 2014 and 2013.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
	As of June 30, 2014 and December 31, 2013, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis.
	The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. Both the accrued warrant liability and compensatory stock options not yet issued use management’s estimate for the expected term, which is based on the safe harbor method as historical exercise information over the term of each security is not readily available. Additionally, the number of compensatory options awarded involves an estimate of management’s performance in relation to the targets set forth in the Company’s Executive Compensation Plan. The following table summarizes the unobservable inputs into the fair value measurement for the accrued warrant liability as of June 30, 2014:
			June 30, 2014
	Description		Fair Value			Valuation Technique		Unobservable Input	Range
	Accrued warrant liability		$	1,024,720		Black-scholes pricing model		Expected term - Years	0.34 - 4.54
	Management believes the value of both the accrued warrant liability and compensatory stock options is more sensitive to a change in the Company’s stock price at the end of the respective reporting period as opposed to a change in one of the unobservable inputs described above.
	The carrying amounts of the Company’s short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	4.  Debt
	On September 30, 2013, the Company entered into a Loan and Security Agreement with Hercules Technology II, L.P. and borrowed $6.0 million (the “Hercules Loan”). In addition to interest and principle payments, the Hercules Loan requires payment of $550,000 at maturity, or upon full repayment if sooner, (the “End-of-Term Fee”). In June 2014, CBLI repaid $4.0 million of the Hercules Loan using net proceeds of $3.3 million from a sale of equity more fully discussed in Note 5, along with $0.7 million of the Company’s cash. A 3% prepayment penalty was waived. The following schedule shows the remaining principal payments due under the Hercules Loan ($2.0 million as of June 30, 2014) for each of the twelve month periods commencing July 1, along with the End-of-Term Fee:
		June 30,
	2015	$	481,903
	2016		788,877
	2017		1,279,220
	2018		—
	2019		—
	Thereafter		—
		$	2,550,000

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	5.  Stockholders’ Equity
	On June 20, 2014, the Company completed a sale of units that were immediately separable into an aggregate of 6,167,400 shares of the Company’s common stock and warrants to purchase up to 3,083,700 additional shares of the Company’s common stock issuable upon the exercise of a warrant. Each unit was sold for $0.5675, which qualified as an “at market” transaction as determined by NASDAQ, resulting in net proceeds of approximately $3.3 million after deducting for placement agent fees and offering expenses. In connection with the sale, the Company issued Series J warrants for 3,083,700 shares of common stock to the purchasers, and 26,432 Series J warrants to the placement agent. Each Series J warrant has an exercise price of $0.56 per share, and will expire five years from the date of issuance. The sale also triggered a reduction in the exercise price 4,577,444 of the Company’s warrants to $0.505.
	On January 16, 2014, the Company completed a public offering of 5,737,706 shares of the Company’s common stock at a price of $1.22 per share, resulting in net proceeds of approximately $6.4 million after deducting for placement agent fees and offering expenses. In connection with the offering, the Company issued Series A warrants for 2,868,853 shares of common stock and Series B warrants for 2,868,853 shares of common stock to the purchasers. Each Series A warrant has an exercise price of $1.22 per share, and will become exercisable six months following the date of issuance and expire five years from the date of issuance. Each Series B warrant has an exercise price of $1.22 per share, and will become exercisable six months following the date of issuance and expire 18 months from the date of issuance. In addition to the warrants issued to the purchasers, the Company also issued Series A warrants for an aggregate of 86,066 shares of common stock and Series B warrants for an aggregate of 86,066 shares of common stock to the placement agent as compensation for completing the offering. The warrants to the placement agent have the same terms, including exercise price, as the warrants issued to investors. The offering also triggered a reduction in the exercise price of 4,421,195 of the Company’s warrants to $1.22.
	The Series A and B warrants contain provisions that could require the Company to settle the warrants in cash, and accordingly, have been classified as a liability. The fair value of the Series A and B warrants amounted to $2,283,092 and was determined based on the following assumptions using the Black-Scholes valuation model:
		June 30, 2014
	Stock Price	$1.23
	Exercise Price	$1.22
	Term in years	0.75 - 2.50
	Volatility	43.06 - 79.86%
	Annual rate of quarterly dividends	0%
	Discount rate- bond equivalent yield	.09 -   .58%
	The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the six months ended June 30, 2014:
		Six Months Ended June 30, 2014
		Total Stock			Weighted Average		Nonvested Stock			Weighted Average
		Options			Exercise Price per		Options			Grant Date Fair
		Outstanding			Share					Value per Share
	31-Dec-13		5,564,833		$	4.14		594,479		$	1.5
	Granted		991,000			0.62		48,750			0.5
	Vested		—			—		(62,500	)		3.21
	Exercised		—			—		—			—
	Forfeited, Canceled		(331,726	)		3.27		(113,750	)		1.45
	30-Jun-14		6,224,107		$	3.63		466,979		$	1.16
	The following is a summary of outstanding stock options as of June 30, 2014:
		As of June 30, 2014
		Stock Options			Vested Stock
		Outstanding			Options
	Quantity		6,224,107			5,757,128
	Weighted-average exercise price	$	3.63		$	3.8
	Weighted Average Remaining Contractual Term (in Years)		6.73			6.56
	Intrinsic value	$	—		$	—
	For the six months ended June 30, 2014 and 2013, the Company granted 991,000 and 863,604 stock options, respectively, with a weighted-average grant date fair value of $0.38 and $1.22, respectively. For the six months ended June 30, 2014 and 2013, the total fair value of options vested was $200,658 and $681,599, respectively.
	As of June 30, 2014, total compensation cost not yet recognized related to unvested stock options was $199,530. The Company expects to recognize this cost over a weighted average period of approximately 1.00 years.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Warrants	'
	6.  Warrants
	In connection with sales of the Company’s common stock and the issuance of debt instruments, warrants were issued with exercise prices ranging from $0.505 to $5.00. The warrants expire between one and seven years from the date of grant, subject to the terms applicable in the agreement. As of June 30, 2014, the Company had warrants outstanding that are exercisable up to 20,614,214 shares of common stock, with a weighted average exercise price of $1.66 per share.

Noncontrolling_Interests

Noncontrolling Interests	6 Months Ended
	Jun. 30, 2014
Noncontrolling Interest [Abstract]	'
Noncontrolling Interests	'
	7.  Noncontrolling Interests
	On June 20, 2014, Bioprocess Capital Ventures (“BCV”), the noncontrolling interest holder in Incuron, contributed 100.0 million Russian rubles (approximately $2.9 million) to Incuron, which increased its ownership interest from 40.78% to 46.06% and decreased CBLI’s ownership percentage from 59.22% to 53.94%. The effect of the changes in CBLI ownership interest in Incuron on CBLI’s equity is shown on the consolidated statement of stockholders’ equity. On August 1, 2014, BCV contributed approximately 80 million Russian rubles (approximately $2.3 million) to Incuron which increased its ownership interest from 46.06% to 53.04%. Effective August 1, 2014, CBLI will no longer consolidate Incuron but will account for its ownership interest using the equity method of accounting.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of CBLI and its subsidiaries, BioLab 612, Incuron and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
	In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2014, along with its results of operations for the three and six month periods ended June 30, 2014 and 2013 and cash flows for the six month periods ended June 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Of the $11.1 million and $10.0 million of cash and cash equivalents at June 30, 2014 and December 31, 2013, respectively, $0.0 million and $3.5 million, respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of June 30, 2014, $3.4 million of the Company’s cash and cash equivalents was restricted to the use of its majority-owned subsidiaries, leaving $7.7 million available for general use.
Significant Customers and Accounts Receivable	'
	Significant Customers and Accounts Receivable
	Grant and contract revenue from the U.S. government accounted for 0% and 1.2% of total revenue for the three and six months ended June 30, 2014, respectively, and 37.7% and 34.8% of total revenue for the three and six months ended June 30, 2013, respectively. Grant and contract revenue received by the Company’s subsidiaries from Russian government agencies accounted for 100% and 98.8% of total revenues for the three and six months ended June 30, 2014, respectively, and 62.3% and 65.2% of total revenues for the three and six months ended June 30, 2013, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future.
	Accounts receivable consist of amounts due under reimbursement contracts with certain government and foreign entities. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 days.
	Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were no allowances for doubtful accounts as of June 30, 2014 and December 31, 2013, as the collection history from the Company’s customers indicated that collection was probable.
Intellectual Property	'
	Intellectual Property
	Costs related to filing and pursuing patent applications are recognized as general and administrative expenses, or G&A expenses, as incurred, since the recoverability of such expenditures is uncertain. Upon marketing approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
Accounting for Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of June 30, 2014, an aggregate of 10.0 million shares of common stock were authorized for issuance under the Plan, of which a total of approximately 1.5 million shares of common stock remained available for future awards. A single participant cannot be awarded more than 400,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s compensation committee.
	In June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of Common Stock. As of June 30, 2014, there are 2.3 million shares of Common Stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i) 10% of the total number of shares of Common Stock outstanding on December 31st of the preceding year, or (ii) 200,000 shares of Common Stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of Common Stock at an amount equal to 85% of the fair market value of the Company’s Common Stock on the offering date or the purchase date, whichever is less.
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the six months ended June 30,
		2014		2013
	Risk-free interest rate	1.59 - 1.98%		0.02 - 1.92%
	Expected dividend yield	0%		0%
	Expected life	5 - 6 Years		5 - 7.3 Years
	Expected volatility	71.24 - 77.99%		80.71 - 89.66%
	“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
	“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
	“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
	“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
Income Taxes	'
	Income Taxes
	No income tax expense was recorded for the three and six months ended June 30, 2014 and 2013, as the Company does not expect to have taxable income for 2014 and did not have taxable income in 2013. A full valuation allowance has been recorded against the Company’s deferred tax asset.
Earnings (Loss) per Share	'
	Earnings (Loss) per Share
	Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of June 30,
	Common Equivalent Securities	2014			2013
	Warrants		20,614,204			10,377,995
	Options		6,224,107			5,683,944
	Total		26,838,311			16,061,939
Contingencies	'
	Contingencies
	From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company is not a party to any pending material litigation that is estimable and probable of loss.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Assumptions Used in Valuing Stock Options Granted	'
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the six months ended June 30,
		2014		2013
	Risk-free interest rate	1.59 - 1.98%		0.02 - 1.92%
	Expected dividend yield	0%		0%
	Expected life	5 - 6 Years		5 - 7.3 Years
	Expected volatility	71.24 - 77.99%		80.71 - 89.66%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of June 30,
	Common Equivalent Securities	2014			2013
	Warrants		20,614,204			10,377,995
	Options		6,224,107			5,683,944
	Total		26,838,311			16,061,939

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Hierarchy for Financial Liabilities Measured on Recurring Basis	'
	The following tables represent the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013:
			As of June 30, 2014
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,024,720		$	1,024,720
	Total liabilities		$	—		$	—		$	1,024,720		$	1,024,720
			As of December 31, 2013
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311		$	1,241,311
	Compensatory stock options not yet issued			—			—			309,450			309,450
	Total liabilities		$	—		$	—		$	1,550,761		$	1,550,761
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	'
	The Company uses the Black-Scholes model to measure the accrued warrant liability and its accrual for compensatory stock options not yet issued. The following are the assumptions used to measure the accrued warrant liability at June 30, 2014 and December 31, 2013, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2:
			June 30, 2014		December 31, 2013
	Stock Price		$0.48		$1.17
	Exercise Price		$0.505 - 5.00		$1.60 - 5.00
	Term in years		0.34 - 4.54		0.59 - 1.91
	Volatility		61.15 - 82.14%		42.52 - 76.03%
	Annual rate of quarterly dividends		0%		0%
	Discount rate- bond equivalent yield		.04 - 1.45%		.08 -  .36%
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	'
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the six months ended June 30, 2014 and 2013:
			Three months ended June 30, 2014						Six months ended June 30, 2014
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	1,436,845		$	—		$	1,241,311		$	309,450
	Issuances			—			—			2,283,092			—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(412,125	)		—			(2,499,683	)		(21,055	)
	Settlements			—			—			—			(288,395	)
	Balance, June 30, 2014		$	1,024,720		$	—		$	1,024,720		$	—
			Three months ended June 30, 2013						Six months ended June 30, 2013
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	7,553,382		$	63,641		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)			(2,795,612	)		—			652,111			—
	Estimates and other changes in fair value (2)			—			197			—			63,838
	Balance, June 30, 2013		$	4,757,770		$	63,838		$	4,757,770		$	63,838
	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the three months ended June 30, 2014 and 2013.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability	'
	The following table summarizes the unobservable inputs into the fair value measurement for the accrued warrant liability as of June 30, 2014:
			June 30, 2014
	Description		Fair Value			Valuation Technique		Unobservable Input	Range
	Accrued warrant liability		$	1,024,720		Black-scholes pricing model		Expected term - Years	0.34 - 4.54

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Summary of Remaining Principal Payments	'
	The following schedule shows the remaining principal payments due under the Hercules Loan ($2.0 million as of June 30, 2014) for each of the twelve month periods commencing July 1, along with the End-of-Term Fee:
		June 30,
	2015	$	481,903
	2016		788,877
	2017		1,279,220
	2018		—
	2019		—
	Thereafter		—
		$	2,550,000

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Warrants Determined by Black-Scholes Valuation Model with Following Assumptions	'
	The fair value of the Series A and B warrants amounted to $2,283,092 and was determined based on the following assumptions using the Black-Scholes valuation model:
		June 30, 2014
	Stock Price	$1.23
	Exercise Price	$1.22
	Term in years	0.75 - 2.50
	Volatility	43.06 - 79.86%
	Annual rate of quarterly dividends	0%
	Discount rate- bond equivalent yield	.09 -   .58%
Summary of Option Award Activity	'
	The following is a summary of option award activity during the six months ended June 30, 2014:
		Six Months Ended June 30, 2014
		Total Stock			Weighted Average		Nonvested Stock			Weighted Average
		Options			Exercise Price per		Options			Grant Date Fair
		Outstanding			Share					Value per Share
	31-Dec-13		5,564,833		$	4.14		594,479		$	1.5
	Granted		991,000			0.62		48,750			0.5
	Vested		—			—		(62,500	)		3.21
	Exercised		—			—		—			—
	Forfeited, Canceled		(331,726	)		3.27		(113,750	)		1.45
	30-Jun-14		6,224,107		$	3.63		466,979		$	1.16
Summary of Outstanding Stock Options	'
	The following is a summary of outstanding stock options as of June 30, 2014:
		As of June 30, 2014
		Stock Options			Vested Stock
		Outstanding			Options
	Quantity		6,224,107			5,757,128
	Weighted-average exercise price	$	3.63		$	3.8
	Weighted Average Remaining Contractual Term (in Years)		6.73			6.56
	Intrinsic value	$	—		$	—

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Line Items]	'	'	'	'	'	'
Cash and cash equivalents at carrying value	$11,103,596	$13,245,397	$11,103,596	$13,245,397	$10,048,466	$25,652,083
Other cash and cash equivalents at carrying value	0	'	0	'	3,500,000	'
Cash and highly liquid investments maturity	'	'	'90 days	'	'	'
General use cash total	7,700,000	'	7,700,000	'	'	'
Allowances for doubtful accounts	0	'	0	'	0	'
Share-based compensation arrangement by share-based payment award, number of shares authorized	10,000,000	'	10,000,000	'	'	'
Share-based compensation arrangement by share-based payment award, number of shares available for grant	1,500,000	'	1,500,000	'	'	'
Share-based compensation arrangement by share-based payment award number of shares limited per year	'	'	400,000	'	'	'
Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms	'	'	'10 years	'	'	'
Income tax expense	0	0	0	0	'	'
2013 ESPP Plan [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Share-based compensation arrangement by share-based payment award, number of shares available for grant	2,300,000	'	2,300,000	'	'	'
Percentage of the total number of shares of common stock outstanding of the preceding year	'	'	10.00%	'	'	'
Share-based compensation arrangement by share-based payment award, number of shares limited per year	200,000	'	200,000	'	'	'
Share-based compensation arrangement by share-based payment award, maximum employee subscription rate	15.00%	'	15.00%	'	'	'
Share-based compensation arrangement by share-based payment award, discount from market price, offering rate	'	'	85.00%	'	'	'
Accounts Receivable [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Credit term	'	'	'30 days	'	'	'
Grant and Contract Revenue from U.S. [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Concentration risk percentage	0.00%	37.70%	1.20%	34.80%	'	'
Grant and Contract Revenue from Outside Non Domestic [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Concentration risk percentage	100.00%	62.30%	98.80%	65.20%	'	'
Majority Owned Subsidiaries [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Subsidiary cash total	$3,400,000	'	$3,400,000	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Assumptions Used in Valuing Stock Options Granted (Detail)

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Employee Stock Option [Member]

Employee Stock Option [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

0.04%

0.08%

1.59%

0.02%

1.45%

0.36%

1.98%

1.92%

Expected dividend yield

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

Expected life

'

'

'

'

'4 months 2 days

'7 months 2 days

'5 years

'5 years

'4 years 6 months 15 days

'1 year 10 months 28 days

'6 years

'7 years 3 months 18 days

Expected volatility

'

'

'

'

61.15%

42.52%

71.24%

80.71%

82.14%

76.03%

77.99%

89.66%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	26,838,311	16,061,939
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	20,614,204	10,377,995
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	6,224,107	5,683,944

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Fair Value Hierarchy for Financial Liabilities Measured on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Liabilities:	'	'
Accrued warrant liability	$1,024,720	$1,241,311
Compensatory stock options not yet issued	'	309,450
Total liabilities	1,024,720	1,550,761
Level 1 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	'	'
Compensatory stock options not yet issued	'	'
Total liabilities	'	'
Level 2 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	'	'
Compensatory stock options not yet issued	'	'
Total liabilities	'	'
Level 3 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	1,024,720	1,241,311
Compensatory stock options not yet issued	'	309,450
Total liabilities	$1,024,720	$1,550,761

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Stock Price	$0.48	$1.17	$0.57	$1.22
Annual rate of quarterly dividends	0.00%	0.00%	'	'
Minimum [Member]	'	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise Price	$0.51	$1.60	'	'
Term in years	'4 months 2 days	'7 months 2 days	'	'
Volatility	61.15%	42.52%	'	'
Discount rate-bond equivalent yield	0.04%	0.08%	'	'
Maximum [Member]	'	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise Price	$5	$5	'	'
Term in years	'4 years 6 months 15 days	'1 year 10 months 28 days	'	'
Volatility	82.14%	76.03%	'	'
Discount rate-bond equivalent yield	1.45%	0.36%	'	'

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accrued Warrant Liability [Member]	'	'	'	'
Beginning balance	$1,436,845	$7,553,382	$1,241,311	$4,105,659
Issuances	'	'	2,283,092	'
Total (gains) or losses, realized and unrealized, included in earnings	-412,125	-2,795,612	-2,499,683	652,111
Settlements	'	'	'	'
Estimates and other changes in fair value	'	'	'	'
Ending balance	1,024,720	4,757,770	1,024,720	4,757,770
Compensatory Stock Options Not Yet Issued [Member]	'	'	'	'
Beginning balance	'	63,641	309,450	'
Issuances	'	'	'	'
Total (gains) or losses, realized and unrealized, included in earnings	'	'	-21,055	'
Settlements	'	'	-288,395	'
Estimates and other changes in fair value	'	197	'	63,838
Ending balance	'	$63,838	'	$63,838

Fair_Value_of_Financial_Instru5

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Parenthetical) (Detail) (USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Debt Instrument Fair Value Carrying Value [Abstract]	'	'
Realized gains or losses	$0	$0

Fair_Value_of_Financial_Instru6

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument Fair Value Carrying Value [Abstract]	'	'
Assets or liabilities	$0	$0

Fair_Value_of_Financial_Instru7

Fair Value of Financial Instruments - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) (Accrued Warrant Liability [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Fair Value	$1,024,720
Valuation Technique	'Black-scholes pricing model
Unobservable Input	'Expected term - Years
Minimum [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Range	'4 months 2 days
Maximum [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Range	'4 years 6 months 15 days

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	0 Months Ended		6 Months Ended		6 Months Ended
	Jun. 20, 2014	Jan. 16, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Sep. 30, 2013
					Hercules Technology II, L.P. [Member]	Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	$6,000,000
Long term debt at maturity	'	'	3,634,034	7,121,388	'	550,000
Repayment of long term debt	'	'	4,000,000	'	4,000,000	'
Net proceeds from sale of equity	3,300,000	6,400,000	9,697,501	'	3,300,000	'
Remaining principal payments	'	'	'	'	2,000,000	'
Debt Instrument Penalty rate	'	'	'	'	3.00%	'
Repayments of debt	'	'	'	'	$700,000	'

Debt_Summary_of_Remaining_Prin

Debt - Summary of Remaining Principal Payments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2014
			Hercules Technology II, L.P. [Member]	Notes Payable To Hercules Technology II, L.P. [Member]
				Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]	'	'	'	'
2015	'	'	'	$481,903
2016	'	'	'	788,877
2017	'	'	'	1,279,220
2018	'	'	'	'
2019	'	'	'	'
Thereafter	'	'	'	'
Total	$3,634,034	$7,121,388	$550,000	$2,550,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended		6 Months Ended
	Jun. 20, 2014	Jan. 16, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 20, 2014	Jan. 16, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of shares issued in public offering	6,167,400	5,737,706	'	'	'	'	'	'	'
Number of warrants issued	3,083,700	'	'	'	'	'	'	'	'
Common stock at a price	'	'	$0.48	'	$0.48	'	$0.57	$1.22	$1.17
Proceeds from Issuance of Common Stock	$3,300,000	$6,400,000	'	'	$9,697,501	'	'	'	'
Number of warrants adjusted due to reduction in exercise price	'	'	'	'	'	'	4,577,444	4,421,195	'
Exercise price of warrants	'	'	'	'	'	'	$0.51	$1.22	'
Fair value of warrants	'	'	-412,125	-2,795,612	-2,499,683	652,111	'	'	'
Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures	'	'	'	'	991,000	863,604	'	'	'
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted-average grant date fair value	'	'	'	'	0.38	1.22	'	'	'
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value	'	'	'	'	200,658	681,599	'	'	'
Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized	'	'	199,530	'	199,530	'	'	'	'
Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized, period for recognition	'	'	'	'	'1 year	'	'	'	'
Series A Warrants [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Fair value of warrants	'	'	'	'	2,283,092	'	'	'	'
Series B Warrants [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Fair value of warrants	'	'	'	'	$2,283,092	'	'	'	'
Purchasers [Member] | Series A Warrants [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants issued	'	2,868,853	'	'	'	'	'	'	'
Warrants exercisable price per share	'	$1.22	'	'	'	'	'	'	'
Warrants expiration period from the date of issuance	'	'5 years	'	'	'	'	'	'	'
Warrants exercisable period from the date of issuance	'	'6 months	'	'	'	'	'	'	'
Purchasers [Member] | Series B Warrants [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants issued	'	2,868,853	'	'	'	'	'	'	'
Warrants exercisable price per share	'	$1.22	'	'	'	'	'	'	'
Warrants expiration period from the date of issuance	'	'18 months	'	'	'	'	'	'	'
Warrants exercisable period from the date of issuance	'	'6 months	'	'	'	'	'	'	'
Purchasers [Member] | Series J [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants issued	3,083,700	'	'	'	'	'	'	'	'
Warrants exercisable price per share	$0.56	'	'	'	'	'	'	'	'
Warrants expiration period from the date of issuance	'5 years	'	'	'	'	'	'	'	'
Placement Agent [Member] | Series A Warrants [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants issued	'	86,066	'	'	'	'	'	'	'
Placement Agent [Member] | Series B Warrants [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants issued	'	86,066	'	'	'	'	'	'	'
Placement Agent [Member] | Series J [Member]	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants issued	26,432	'	'	'	'	'	'	'	'
Warrants exercisable price per share	$0.56	'	'	'	'	'	'	'	'
Warrants expiration period from the date of issuance	'5 years	'	'	'	'	'	'	'	'

Stockholders_Equity_Warrants_D

Stockholders' Equity - Warrants Determined by Black-Scholes Valuation Model with Following Assumptions (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock Price	$0.48	$1.17	$0.57	$1.22
Annual rate of quarterly dividends	0.00%	0.00%	'	'
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Exercise Price	$0.51	$1.60	'	'
Term in years	'4 months 2 days	'7 months 2 days	'	'
Volatility	61.15%	42.52%	'	'
Discount rate- bond equivalent yield	0.04%	0.08%	'	'
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Exercise Price	$5	$5	'	'
Term in years	'4 years 6 months 15 days	'1 year 10 months 28 days	'	'
Volatility	82.14%	76.03%	'	'
Discount rate- bond equivalent yield	1.45%	0.36%	'	'
Black Scholes Stock Price Valuation Model [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock Price	$1.23	'	'	'
Exercise Price	$1.22	'	'	'
Annual rate of quarterly dividends	0.00%	'	'	'
Black Scholes Stock Price Valuation Model [Member] | Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Term in years	'9 months	'	'	'
Volatility	43.06%	'	'	'
Discount rate- bond equivalent yield	0.09%	'	'	'
Black Scholes Stock Price Valuation Model [Member] | Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Term in years	'2 years 6 months	'	'	'
Volatility	79.86%	'	'	'
Discount rate- bond equivalent yield	0.58%	'	'	'

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Option Award Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Total Stock Options Outstanding, Beginning balance	5,564,833
Total Stock Options Outstanding, Granted	991,000
Total Stock Options Outstanding, Vested	'
Total Stock Options Outstanding, Exercised	'
Total Stock Options Outstanding, Forfeited, Canceled	-331,726
Total Stock Options Outstanding, Ending balance	6,224,107
Weighted Average Exercise Price per Share, Beginning balance	$4.14
Weighted Average Exercise Price per Share, Granted	$0.62
Weighted Average Exercise Price per Share, Vested	'
Weighted Average Exercise Price per Share, Exercised	'
Weighted Average Exercise Price per Share, Forfeited, Canceled	$3.27
Weighted Average Exercise Price per Share, Ending balance	$3.63
Nonvested Stock Options, Beginning balance	594,479
Nonvested Stock Options, Granted	48,750
Nonvested Stock Options, Vested	-62,500
Nonvested Stock Options, Exercised	'
Nonvested Stock Options, Forfeited, Canceled	-113,750
Nonvested Stock Options, Ending balance	466,979
Weighted Average Grant Date Fair Value per Share, Beginning balance	$1.50
Weighted Average Grant Date Fair Value per Share, Granted	$0.50
Weighted Average Grant Date Fair Value per Share, Vested	$3.21
Weighted Average Grant Date Fair Value per Share, Exercised	'
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled	$1.45
Weighted Average Grant Date Fair Value per Share, Ending balance	$1.16

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Outstanding Stock Options (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
			Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock Options Outstanding, Quantity	6,224,107	5,564,833	6,224,107
Stock Options Outstanding, Weighted-average exercise price	$3.63	$4.14	$3.63
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	'	'	'6 years 8 months 23 days
Stock Options Outstanding, Intrinsic value	'	'	'
Vested Stock Options, Quantity	'	'	5,757,128
Vested Stock Options, Weighted-average exercise price	'	'	$3.80
Vested Stock Options, Weighted Average Remaining Contractual Term (in Years)	'	'	'6 years 6 months 22 days
Vested Stock Options, Intrinsic value	'	'	'

Warrants_Additional_Informatio

Warrants - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
Class of Warrant or Right [Line Items]	'
Class of warrants or right, exercise price of warrants or rights	1.66
Class of warrants or right, number of securities called by warrants or rights (in shares)	20,614,214
Minimum [Member]	'
Class of Warrant or Right [Line Items]	'
Class of warrants or right, exercise price of warrants or rights	0.505
Warrants expiration term	'1 year
Maximum [Member]	'
Class of Warrant or Right [Line Items]	'
Class of warrants or right, exercise price of warrants or rights	5
Warrants expiration term	'7 years

Noncontrolling_Interests_Addit

Noncontrolling Interests - Additional Information (Detail)	0 Months Ended				6 Months Ended			6 Months Ended
In Millions, unless otherwise specified	Jun. 20, 2014	Jun. 20, 2014	Aug. 01, 2014	Aug. 01, 2014	Jun. 30, 2014	Jun. 30, 2014	Aug. 01, 2014	Jun. 30, 2014	Jun. 30, 2014	Aug. 01, 2014
	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Minimum [Member]	Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]	Maximum [Member]
	Incuron, LLC [Member]	Incuron, LLC [Member]	Incuron, LLC [Member]	Incuron, LLC [Member]	C B L I [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	C B L I [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]
	USD ($)	RUB	Subsequent Event [Member]	Subsequent Event [Member]			Subsequent Event [Member]			Subsequent Event [Member]
			USD ($)	RUB
Noncontrolling Interest [Line Items]	'	'	'	'	'	'	'	'	'	'
Payments to acquire additional interest in subsidiaries	$2.90	100	$2.30	80	'	'	'	'	'	'
Noncontrolling interest, ownership percentage by noncontrolling owners	'	'	'	'	'	40.78%	46.06%	'	46.06%	53.04%
Ownership interest in Incuron, LLC majority-owned subsidiary	'	'	'	'	53.94%	'	'	59.22%	'	'